These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 9454653)

  • 1. No evidence exists for methylation inactivation of the p16 tumor suppressor gene in ovarian carcinogenesis.
    Ryan A; Al-Jehani RM; Mulligan KT; Jacobs IJ
    Gynecol Oncol; 1998 Jan; 68(1):14-7. PubMed ID: 9454653
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Methylation of the 5' CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing.
    Gonzalez-Zulueta M; Bender CM; Yang AS; Nguyen T; Beart RW; Van Tornout JM; Jones PA
    Cancer Res; 1995 Oct; 55(20):4531-5. PubMed ID: 7553622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of p16 (CDKN2/MTS-1/INK4A) alterations in primary sporadic uveal melanoma.
    Merbs SL; Sidransky D
    Invest Ophthalmol Vis Sci; 1999 Mar; 40(3):779-83. PubMed ID: 10067984
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular analysis of P16(Ink4)/CDKN2 and P15(INK4B)/MTS2 genes in primary human testicular germ cell tumors.
    Heidenreich A; Gaddipati JP; Moul JW; Srivastava S
    J Urol; 1998 May; 159(5):1725-30. PubMed ID: 9554401
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aberrant p16 expression is correlated with hemizygous deletions at the 9p21-22 chromosome region in non-small cell lung carcinomas.
    Spanakis NE; Gorgoulis V; Mariatos G; Zacharatos P; Kotsinas A; Garinis G; Trigidou R; Karameris A; Tsimara-Papastamatiou H; Kouloukousa M; Manolis EN; Kittas C
    Anticancer Res; 1999; 19(3A):1893-9. PubMed ID: 10470133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Investigations to the influence of tumor supressor gene p16 inactivation on the prognosis of head and neck squamous cell carcinoma].
    Koscielny S; V Eggeling F; Dahse R
    Laryngorhinootologie; 2004 Jun; 83(6):374-80. PubMed ID: 15197677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CDKN2A gene inactivation in epithelial sporadic ovarian cancer.
    Niederacher D; Yan HY; An HX; Bender HG; Beckmann MW
    Br J Cancer; 1999 Aug; 80(12):1920-6. PubMed ID: 10471040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of chromosome 9 in human ovarian neoplasia identifies frequent genetic imbalance on 9q and rare alterations involving 9p, including CDKN2.
    Schultz DC; Vanderveer L; Buetow KH; Boente MP; Ozols RF; Hamilton TC; Godwin AK
    Cancer Res; 1995 May; 55(10):2150-7. PubMed ID: 7743516
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Homozygous deletions at chromosome 9p21 and mutation analysis of p16 and p15 in microdissected primary non-small cell lung cancers.
    Packenham JP; Taylor JA; White CM; Anna CH; Barrett JC; Devereux TR
    Clin Cancer Res; 1995 Jul; 1(7):687-90. PubMed ID: 9816033
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of p16INK4a alterations and 9p21 loss of heterozygosity in locally advanced laryngeal squamous cell carcinoma.
    Bazan V; Zanna I; Migliavacca M; Sanz-Casla MT; Maestro ML; Corsale S; Macaluso M; Dardanoni G; Restivo S; Quintela PL; Bernaldez R; Salerno S; Morello V; Tomasino RM; Gebbia N; Russo A
    J Cell Physiol; 2002 Sep; 192(3):286-93. PubMed ID: 12124774
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low frequency of p16/CDKN2A methylation in sporadic melanoma: comparative approaches for methylation analysis of primary tumors.
    Gonzalgo ML; Bender CM; You EH; Glendening JM; Flores JF; Walker GJ; Hayward NK; Jones PA; Fountain JW
    Cancer Res; 1997 Dec; 57(23):5336-47. PubMed ID: 9393758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. p16 overexpression: a potential early indicator of transformation in ovarian carcinoma.
    Shigemasa K; Hu C; West CM; Clarke J; Parham GP; Parmley TH; Korourian S; Baker VV; O'Brien TJ
    J Soc Gynecol Investig; 1997; 4(2):95-102. PubMed ID: 9101469
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased loss of chromosome 9p21 but not p16 inactivation in primary non-small cell lung cancer from smokers.
    Sanchez-Cespedes M; Decker PA; Doffek KM; Esteller M; Westra WH; Alawi EA; Herman JG; Demeure MJ; Sidransky D; Ahrendt SA
    Cancer Res; 2001 Mar; 61(5):2092-6. PubMed ID: 11280771
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DNA studies underestimate the major role of CDKN2A inactivation in oral and oropharyngeal squamous cell carcinomas.
    Wu CL; Roz L; McKown S; Sloan P; Read AP; Holland S; Porter S; Scully C; Paterson I; Tavassoli M; Thakker N
    Genes Chromosomes Cancer; 1999 May; 25(1):16-25. PubMed ID: 10221335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chromosome 9p21 loss and p16 inactivation in primary sclerosing cholangitis-associated cholangiocarcinoma.
    Ahrendt SA; Eisenberger CF; Yip L; Rashid A; Chow JT; Pitt HA; Sidransky D
    J Surg Res; 1999 Jun; 84(1):88-93. PubMed ID: 10334895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deletional, mutational, and methylation analyses of CDKN2 (p16/MTS1) in primary and metastatic prostate cancer.
    Jarrard DF; Bova GS; Ewing CM; Pin SS; Nguyen SH; Baylin SB; Cairns P; Sidransky D; Herman JG; Isaacs WB
    Genes Chromosomes Cancer; 1997 Jun; 19(2):90-6. PubMed ID: 9171999
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deletion map of chromosome 9 and p16 (CDKN2A) gene alterations in neuroblastoma.
    Takita J; Hayashi Y; Kohno T; Yamaguchi N; Hanada R; Yamamoto K; Yokota J
    Cancer Res; 1997 Mar; 57(5):907-12. PubMed ID: 9041193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loss of heterozygosity and mutation analysis of the p16 (9p21) and p53 (17p13) genes in squamous cell carcinoma of the head and neck.
    González MV; Pello MF; López-Larrea C; Suárez C; Menéndez MJ; Coto E
    Clin Cancer Res; 1995 Sep; 1(9):1043-9. PubMed ID: 9816078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic alterations in gastrinomas and nonfunctioning pancreatic neuroendocrine tumors: an analysis of p16/MTS1 tumor suppressor gene inactivation.
    Muscarella P; Melvin WS; Fisher WE; Foor J; Ellison EC; Herman JG; Schirmer WJ; Hitchcock CL; DeYoung BR; Weghorst CM
    Cancer Res; 1998 Jan; 58(2):237-40. PubMed ID: 9443399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chromosome 9p allelic loss and p16/CDKN2 in breast cancer and evidence of p16 inactivation in immortal breast epithelial cells.
    Brenner AJ; Aldaz CM
    Cancer Res; 1995 Jul; 55(13):2892-5. PubMed ID: 7796417
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.